Biotech research firm Orig3n picks up Series B funding
Boston-based Orig3n, a biotech research company focused on genetics and regenerative medicine, has secured Series B funding, raising a total of over $50 million to date since the firm's inception in 2014. Haitong International was the lead investor. Other investors that participated in the round included Hatteras Venture Partners, Alexandria Venture Investments, Labcorp, Spectrum Health Ventures, 180 degree capital, VECTR Ventures, KTB Ventures, DEFTA Partners, MMIC Investment Holdings and Mountain Group Partners.
12 July 2018•3 mins read
